These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 31155560)

  • 1. A 3D-QSAR Analysis of CDK2 Inhibitors Using FMO Calculations and PLS Regression.
    Yoshida T; Hirono S
    Chem Pharm Bull (Tokyo); 2019; 67(6):546-555. PubMed ID: 31155560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular docking and MD simulation studies of 4-thiazol-N-(pyridin-2-yl)pyrimidin-2-amine derivatives as novel inhibitors targeted to CDK2/4/6.
    Liang JD; Zhang YE; Qin F; Chen WN; Jiang WM; Fang Z; Liang XL; Zhang Q; Li J
    J Cancer Res Clin Oncol; 2024 Jun; 150(6):302. PubMed ID: 38856753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular modeling studies to characterize N-phenylpyrimidin-2-amine selectivity for CDK2 and CDK4 through 3D-QSAR and molecular dynamics simulations.
    Chohan TA; Chen JJ; Qian HY; Pan YL; Chen JZ
    Mol Biosyst; 2016 Apr; 12(4):1250-68. PubMed ID: 26883408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-based and multiple potential three-dimensional quantitative structure-activity relationship (SB-MP-3D-QSAR) for inhibitor design.
    Du QS; Gao J; Wei YT; Du LQ; Wang SQ; Huang RB
    J Chem Inf Model; 2012 Apr; 52(4):996-1004. PubMed ID: 22480344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Modeling and Design Studies of Purine Derivatives as Novel CDK2 Inhibitors.
    Zhang G; Ren Y
    Molecules; 2018 Nov; 23(11):. PubMed ID: 30423939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular insights of benzodipyrazole as CDK2 inhibitors: combined molecular docking, molecular dynamics, and 3D QSAR studies.
    Guttikonda V; Raavi D; Maadwar SK; Gade DR
    J Recept Signal Transduct Res; 2015; 35(5):439-49. PubMed ID: 25902329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How good are ensembles in improving QSAR models? The case with eCoRIA.
    Khedkar VM; Joseph J; Pissurlenkar R; Saran A; Coutinho EC
    J Biomol Struct Dyn; 2015; 33(4):749-69. PubMed ID: 24754910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of cyclin-dependent kinase 2 inhibitor potency using the fragment molecular orbital method.
    Mazanetz MP; Ichihara O; Law RJ; Whittaker M
    J Cheminform; 2011 Jan; 3(1):2. PubMed ID: 21219630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular simulation studies on the binding selectivity of 2-anilino-4-(thiazol-5-yl)-pyrimidines in complexes with CDK2 and CDK7.
    Chohan TA; Qian HY; Pan YL; Chen JZ
    Mol Biosyst; 2016 Jan; 12(1):145-61. PubMed ID: 26565382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular dynamics and QM/MM-based 3D interaction analyses of cyclin-E inhibitors.
    Pasha FA; Neaz MM
    J Mol Model; 2013 Feb; 19(2):879-91. PubMed ID: 23086460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An in silico exploration of the interaction mechanism of pyrazolo[1,5-a]pyrimidine type CDK2 inhibitors.
    Li Y; Gao W; Li F; Wang J; Zhang J; Yang Y; Zhang S; Yang L
    Mol Biosyst; 2013 Sep; 9(9):2266-81. PubMed ID: 23864105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment and acceleration of binding energy calculations for protein-ligand complexes by the fragment molecular orbital method.
    Otsuka T; Okimoto N; Taiji M
    J Comput Chem; 2015 Nov; 36(30):2209-18. PubMed ID: 26400829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular modeling studies of 4,5-dihydro-1H-pyrazolo[4,3-h] quinazoline derivatives as potent CDK2/Cyclin a inhibitors using 3D-QSAR and docking.
    Ai Y; Wang ST; Sun PH; Song FJ
    Int J Mol Sci; 2010 Sep; 11(10):3705-24. PubMed ID: 21152296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Free-energy force-field three-dimensional quantitative structure-activity relationship analysis of a set of p38-mitogen activated protein kinase inhibitors.
    Romeiro NC; Albuquerque MG; de Alencastro RB; Ravi M; Hopfinger AJ
    J Mol Model; 2006 Sep; 12(6):855-68. PubMed ID: 16541250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 3D-QSAR CoMFA study on oxindole derivatives as cyclin dependent kinase 1 (CDK1) and cyclin dependent kinase 2 (CDK2) inhibitors.
    Singh SK; Dessalew N; Bharatam PV
    Med Chem; 2007 Jan; 3(1):75-84. PubMed ID: 17266627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 3D-QSAR and docking studies on pyrazolo[4,3-h]qinazoline-3-carboxamides as cyclin-dependent kinase 2 (CDK2) inhibitors.
    Lan P; Chen WN; Xiao GK; Sun PH; Chen WM
    Bioorg Med Chem Lett; 2010 Nov; 20(22):6764-72. PubMed ID: 20869873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular modelling on small molecular CDK2 inhibitors: an integrated approach using a combination of molecular docking, 3D-QSAR and pharmacophore modelling.
    Yuan H; Liu H; Tai W; Wang F; Zhang Y; Yao S; Ran T; Lu S; Ke Z; Xiong X; Xu J; Chen Y; Lu T
    SAR QSAR Environ Res; 2013 Oct; 24(10):795-817. PubMed ID: 23941641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decoding molecular mechanism of inhibitor bindings to CDK2 using molecular dynamics simulations and binding free energy calculations.
    Chen J; Pang L; Wang W; Wang L; Zhang JZH; Zhu T
    J Biomol Struct Dyn; 2020 Mar; 38(4):985-996. PubMed ID: 30843759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Computational approach for generating robust models for discovering novel molecules as Cyclin Dependent Kinase 4 inhibitors.
    Divya V; Pushpa VL; Sarithamol S; Manoj KB
    J Mol Graph Model; 2018 Jun; 82():48-58. PubMed ID: 29680736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 4D-QSAR and MIA-QSAR study on the Bruton's tyrosine kinase (Btk) inhibitors.
    Ma W; Wang Y; Chu D; Yan H
    J Mol Graph Model; 2019 Nov; 92():357-362. PubMed ID: 31450065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.